| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| MSF | macrophage slowing factor; macrophage spreading factor; Medicins sans Frontieres [Doctors without Bo... |
| MAF | macrophage activation factor; macrophage agglutinating factor; maximum atrial fragmentation; minimum... |
| GRF | gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow... |
| MIF | macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator... |
| GM-CSF | Granulocyte colony-stimulating factor , granulocyte-macrophage colony-stimulating factor |
|---|---|
| G-CSF | Granulocyte-Macrophage Colony-Stimulating Factor , Granulocyte Colony-Stimulating Factor |
| EGFr | Epithelial Growth Factor receptors |
| PDGFR | Platelet Derived Growth Factor Receptors |
| VEGFR | Vascular Endothelial Growth Factor Receptors |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| receptors, macrophage colony-stimulating factor | Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response. (12 Dec 1998) |
|---|
| receptors, granulocyte-macrophage colony-stimulating factor | Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor. (12 Dec 1998) |
|---|---|
| macrophage-activating factor | An agent that stimulates macrophages to attack and ingest cancer cells. They are secreted by stimulated lymphocytes that prime macrophages to become non-specifically cytotoxic to tumours. They also modulate the expression of macrophage cell surface ia antigens. One maf is interferon-gamma (interferon type II). Other factors antigenically distinct from ifn-gamma have also been identified. (12 Dec 1998) |
| macrophage colony-stimulating factor | <growth factor> A glycoprotein growth factor that causes the committed cell line to proliferate and mature into macrophages. A cytokine synthesised by mesenchymal cells that stimulates pluripotent stem cells of bone marrow into differentiating towards the production of monocytes (mononuclear phagocytes). The compound stimulates the survival, proliferation, and differentiation of haematopoietic cells of the monocyte-macrophage series. It is a disulfide-bonded glycoprotein dimer with a mw of 70 kD and binds to a single class of high affinity receptor which is identical to the product of the c-fms proto-oncogene. See: colony-stimulating factors. Chemical name: Colony-stimulating factor 1 Acronym: M-CSF (12 Dec 1998) |
| macrophage inhibition factor | <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion. (18 Nov 1997) |
| granulocyte-macrophage colony-stimulating factor | <growth factor, haematology, oncology> An acidic glycoprotein of mw 23 kD with internal disulfide bonds. It is produced in response to a number of inflammatory mediators by mesenchymal cells present in the haemopoietic environment and at peripheral sites of inflammation. It stimulates the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from foetal liver progenitor cells. It also has some functional activities in mature granulocytes and macrophages. It is used to promote the recovery of the white blood cells following chemotherapy. Chemical name: Colony-stimulating factor 2 See: colony-stimulating factor. Acronym: GM-CSF (12 Dec 1998) |
| receptors, atrial natriuretic factor | Cell surface proteins that bind atrial natriuretic factor with high affinity and trigger intracellular changes influencing the behaviour of cells. (12 Dec 1998) |
| receptors, colony-stimulating factor | Cell surface receptors for colony-stimulating factors, local mediators, and hormones that regulate the survival, proliferation, and differentiation of haemopoietic cells. (12 Dec 1998) |
| receptors, epidermal growth factor-urogastrone | Glycoproteins of about 170 kD that have protein kinase activity and span the plasma membranes of growing cells, including tumours. They are activated by the binding of epidermal growth factor-urogastrone which then initiates DNA and protein synthesis. They are not found on mitotically quiescent cells except in the stomach where they control the synthesis and release of digestive enzymes and gastric acid. Transforming growth factor alpha also binds to and activates these receptors. (12 Dec 1998) |
| receptors, fibroblast growth factor | Specific molecular sites or structures on cell membranes that react with fibroblast growth factors (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity. (12 Dec 1998) |
| receptors, granulocyte-colony-stimulating factor | Receptors that bind and internalise granulocyte-colony-stimulating factor. Their mw is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells. (12 Dec 1998) |
| receptors, growth factor | Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells. (12 Dec 1998) |
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |
| receptors, insulin-like-growth-factor II | Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity. (12 Dec 1998) |
| receptors, nerve growth factor | Cell surface receptors that bind nerve growth factor (ngf) and trigger intracellular changes influencing the behaviour of cells. Nerve growth factor receptors mediate the effects of nerve growth factor on the survival and growth of neurons. (12 Dec 1998) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|